Atherosclerosis reduction and improved glucose control the ABCA1 agonist CS6253. In vitro and in vivo mechanism of action studies
26 August 2017 (12:35 - 13:25)
Organised by:
Abstract
Slides
About the speaker
Resverlogix Inc., San Francisco (United States of America)
6 More presentations in this session
Mr A. Minoshima (Asahikawa, JP)
Doctor L. Hobohm (Mainz, DE)
Doctor E. Pardali (Munster, DE)
Access the full session
The Event
ESC Congress 2017
26 August 2017
12:35 CET
You may be interested in
Webinar
15 November 2021
Congress Presentation
